News | February 24, 2026
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
